International Scholarly Research Notices

International Scholarly Research Notices / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 851541 |

Emanuel Calenoff, "Interplaying Factors That Effect Multiple Sclerosis Causation and Sustenance", International Scholarly Research Notices, vol. 2012, Article ID 851541, 27 pages, 2012.

Interplaying Factors That Effect Multiple Sclerosis Causation and Sustenance

Academic Editor: B. Moreno-López
Received01 Nov 2011
Accepted11 Dec 2011
Published23 Jan 2012


The author hypothesized that multiple sclerosis (MS) is a humoral autoimmune disease, caused by faulty interplay between myelin-specific, dimeric IgE, specifically competing non-IgE antibodies and IgE-triggered degranulating mast cells. The principal fault was believed to be insufficient quantity of protective, specific non-IgE antibodies. Also conjectured was the possibility of an unexpected and adverse immune suppression caused by none-MS pharmaceuticals being consumed by patients for their MS or for other conditions. To test both hypotheses, a mimotopic, peptide antigen-based, serum immunoassay was developed to measure dimer-bound IgE excess among MS patients, wherein the IgE specifically complexes with two or more myelin surface epitopes at an interval of 40–100 Angstroms, a separation critical for mast cell degranulation and cell damaging effect. MS test sensitivity and specificity, when analyzing five previously untreated patients for dimeric IgE presence, was 100%. In direct comparison, twenty age- and gender-matched female and male control subjects were test negative. Analysis of 35 multiple sclerosis patients, who were concomitantly being treated with potentially immunosuppressive pharmaceuticals, appeared to show the substances’ negative effect upon MS causation, progression, or specific immunoassay performance. Therefore, MS is likely an autoimmune disease caused by IgE-mediated mast cell degranulation possibly in conjunction with immunosuppressive agents.

1. Introduction

While it is commonly understood that multiple sclerosis (MS) is an autoimmune disease of multifactorial etiology, the exact mechanism of causation has not yet been elucidated. Consequently, disease-specific MS therapy has not advanced beyond the use of interferons and immunosuppressive agents, the application of which is now more than thirty-year old [1, 2] and of questionable, long-term efficacy [3].

Based upon his early work [4] and the work of other investigators [511], the author hypothesized that MS is a humoral autoimmune disease, caused by faulty interplay between myelin-specific IgE, competing specific non-IgE antibodies, and IgE-triggered, degranulating mast cells. Affected mast cells are likely to expel proteolytic enzymes and possibly other factors which damage or destroy targeted myelin and the axons that are sheathed by it.

To test the hypothesis, a mimotopic, peptide antigen-based, serum immunoassay was developed to measure dimer-bound IgE excess among MS patients, wherein the IgE specifically complexes with two or more myelin surface epitopes at an interval of 40−100 Ångströms, a separation critical for mast cell degranulation [12] and tissue-damaging effect.

Because MS patients often consume numerous medications, some started before observed disease onset, questions arise about the medications’ effect upon (1) disease origin, (2) serum antibody test function, and (3) hindrance of normal and protective, humoral immune processes.

Epitope-specific IgE is but one isotype involved in the myelin inflammatory process as other investigators have also documented the presence of myelin-specific IgA, IgG, and IgM [13]. Concomitantly present, the differing isotypes are likely to be cross-competitive for epitopic antigens. An analytical method was therefore developed to measure this potential competition and a determination made whether the competition exists and is likely part of the MS autoimmune process.

The analytical method entailed quantification of the ratio of myelin epitope-specific IgE relative to the sum of the matching myelin-specific non-IgE isotypes. In order to simplify the process, the non-IgE antibody level was determined by measuring epitope-specific human kappa plus lambda chains and subtracting the matching epitope-specific IgE. With experience, it became obvious that the specific IgE subtraction was unnecessary as the IgE was exceedingly small in comparison to the matching non-IgE antibodies.

Thereafter, the evolved MS test employed the formula: IgE/(kappa + lambda). Individual humoral epitopes were mimicked by single peptides that were 5 amino acids in length [4], the size that the author had previously estimated would fit into a single antibody Fab site.

When analyzing surface pentameric structures of individual myelin proteins for potentially serving as humoral epitopes (Section 2) and comparing each structure against surface pentamers on all human genome proteins, it was noted that singular, potentially MS-associated, mimotopic peptides displayed amino acid sequences that were located on the surface of a single, specific myelin protein and on no other protein transcribed from the human genome. Those unique pentamers were employed in the MS test development.

2. Materials and Methods

The Hopp and Woods hydrophilicity method for locating epitopic sites on linear protein sequences [15] was used to predict the humoral epitopes on (a) myelin proteolipid protein (PLP, [16]); (b) myelin oligodendrocyte glycoprotein (MOG, [17]); (c) myelin basic protein (MBP) Isoforms 1 [18], 2 [19] and 3 [20]; (d) oligodendrocyte myelin glycoprotein [21], (e) Claudin 11 [22].

In order to estimate the functional distance (in Ångströms) between epitopes on the surface of each myelin protein, as depicted on its Hopp and Woods plot, the following tasks were per formed. (1)The average diameter of constituent amino acids was determined by (a) comparing the mass of each amino acid relative to the mass of alanine with its known diameter of 6.9 Ångströms [14]; (b) multiplying individual mass ratios times 6.9 Ångströms to obtain estimated amino acid diameter s for the non-alanine amino acids; (c) averaging the resulting amino acid diameters to obtain a n overall average amino acid diameter of 10.6 Ångströms (Table 1).(2)Individual Hopp and Woods, Excel X-Y plots of each protein’s amino acid sequence were modified so as to only depict the protein’s hydrophilic surface, either extracellular or intracellular, as if flattened by trimming away all amino acids that were functionally hydrophobic, and likely to be located in the protein interior, but leaving 2 on each hydrophilic edge to reflect infolding toward the protein center (Figures 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15).(3)The bridging distance between dimeric surface epitopes on individual myelin proteins was estimated by multiplying the intervening amino acids number by 10.6 Ångströms per amino acid.(4)Because a protein surface is not flat but oscillates in depth, sera from an age- and gender-varied MS-negative control group were sequentially tested to measure dimer-point, myelin epitope-specific IgE/(kappa + lambda) values while reducing the estimated dimeric distances in 5 percent intervals to find a reduction percentage to use as a factorial adjustment which simulated staircase dips in normally rolling surface contours of proteins and thus afforded functionally negative test results for the controls (no ideal dimers present). A 25% reduction of the linear distances attained in Step 3 between dimeric epitopes afforded test-negative results for all initially tested, negative-control serum samples by exhibiting no more than one dimer point as being IgE/(kappa + lambda) test positive.(5)In validation, when testing positive control MS patient sera and employing the 25% reduction factor, dimer bridging, test-positive values were attained whose corresponding epitopes’ separation ranged from between 40 to 100 Ångströms, thus indicating a likelihood of mast cell degranulation. Claudin 11 and oligodendrocyte myelin glycoprotein lacked IgE dimer bridging sites and were, therefore, not analyzed further. Pathological dimer bridging values and locations are depicted in Figures 49 for MOG and Figures 1015 for MBP.

Estimation of average amino acid diameter
Molar massAmino acidsNanometer diameterDiameter in Ångströms

133.1DAspartic acid1.0310.3
147.1EGlutamic acid1.1411.4

Average Ångströms diameter per amino acid 10.6


A similar contour-mapping approach was not used for PLP because it has but one structurally unique epitope expressed on the myelin surface, ADARM (Figures 1, 2, 3). However, PLP molecules are highly prevalent on myelin and correctly spaced (65–71 Ångströms) between monomers [23] so as to serve as ideal IgE dimer-binding sites, notwithstanding allowance for the 25% rolling contour adjustment.

In Figure 1, Proteolipid protein Isoform 1 (PLP1) is displayed as a Hopp and Woods XY plot with eleven vertical columns. The leftmost column depicts the amino acid sequence number of the protein chain. The second column from the left lists the sequential, corresponding amino acids. The sixth, left-most, column displays the hydrophilic index (HI) of each listed amino acid. The tenth column from the left depicts the sum-of-seven, continuous amino acids, hydrophilic index value of each amino acid derived by adding to its hydrophilic index (HI) the indices of the 3 amino acids that precede it plus the indices of the three amino acids that follow it. Areas that are net hydrophilic (yellow highlighted) are apt to be on the protein surface while those that are net hydrophobic (uncolored) would be on the protein edge or imbedded within the protein center. The protein surface can either be extracellular or intracellular.

MOG has been shown to be differentially expressed in various isoforms. However, for the purpose of identifying the potential array of MOG humoral epitopes possible on all isoforms and the epitopes’ utility in dimer formation, analysis of MOG Sanger Institute Isomer 1 (Figures 49) proved sufficient. The analysis illustrated the presence of two potential disease-functional dimer sites on the oligodendrocyte, extracellular MOG portion (Figures 5 and 6) and two potential subsurface, intracellular dimer sites (Figures 8 and 9) if the latter were somehow immunosurveillance exposed by myelin surface (oligodendrocyte surface) disruption. By experience, accurate representation of an antibody binding site mandated exhibiting a unique pentamer flanked by an amino acid on each side.

Myelin basic protein, an oligodendrocyte intracellular protein also potentially accessible by myelin surface disruption, exhibits a more complex array of potentially tar getable epitopes and dimer conditions than PLP or MOG. All potential dimer sites are exhibited by a combination of myelin basic protein Isoform 1 (Figures 1012), Isoform 2 (Figures 13-14), and Isoform 3 (Figure 15). For epitope-mapping, singularly unique protein surface regions longer than 5 amino acids were subdivided into overlapping pentamers to represent all possible-single-antibody binding sites (i.e., Figure 10).

2.1. Microtiter Test Plate Layout

As depicted in Figure 16, the basic MS test plate contained 14 mimotopic peptides corresponding to the myelin epitopes illustrated in Figures 1 through 15. Each peptide construct (Mimotopes Pty, Clayton, Australia) applied to the microplate wells comprised a mimotopic peptide preceded by an aminated hydrophilic linker, 8-amino-3,6-dioxaoctanoic acid2 (amino-ADOOA-ADOOA). The epsilon amino group on peptide lysine residues was blocked with a (4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) group, to prevent undesirable, lateral binding when attaching peptide constructs to test plate wells via their free amide groups.

2.2. Peptide Constructs Formulation

Each construct was dissolved in pH 7.2 phosphate buffered saline (PBS) immobilization buffer (Product no. 28372, Thermo Scientific, Rockford, IL, USA), at an assay optimum concentration (Table 2).

Microgram of mimotopic peptide construct per milliliter of coating buffer for MS test microplate wells
Peptide amino Acid Sequence of amino-ADOOA-ADOOA-peptide Construct ADOOA-peptide constructPeptide Construct μg/mL ConcentrationConstruct molar mass (kilodaltons)

(1) ADARM0.260.56
(2) HSYQE0.310.66
(3) RNVRF0.330.69
(4) VTLRI0.280.6
(5) IENLH0.290.62
(6) NLHRTFFE0.51.06
(7) KTGQF0.270.58
(8) DNTFKD0.390.82
(9) HGRTQ0.280.6
(10) LQTIQE0.340.73
(11) PKNAW0.340.73
(12) QDTAVT0.30.63
(13) YKDSHHPA0.450.95
(14) DNEVFGEA0.50.9

2.3. Peptide Constructs Application

100 μL of each peptide construct solution was applied in quadruplicate to 96-well, amide-binding, maleic anhydride-activated, white 96- well plates (Thermo Scientific, Product no. 15108). Four wells were left blank for plate background determination. The plates were covered with acetate plate sealers (Thermo Scientific, Product no. 3501) and the construct solutions incubated at 21−26 degrees C for 18−24 hrs.

2.4. Plate Blocking Procedure

120 μL of HSA background blocking solution (10 mg recombinant human serum albumin per mL immobilization buffer) was applied per well. The construct/blocking solutions were incubated at 21–26 degrees C for 18–24 hrs and plates aspirated and dried.

2.5. Lysine Deprotection Procedure

200 μL of a 2% solution of hydrazine monohydrate (Sigma Chemical Company, St. Louis, MO, Product no. 207942) in DMSO (dimethyl sulfoxide, Thermo Scientific Product No. 20688) was applied per well and incubated at 21–26 degrees C for 10 minutes. The hydrazine solution was aspirated and the procedure repeated two additional times. 250 μL of phosphate buffered saline with 0.05% Tween-20 (PBST, Thermo Scientific Product no. 28320) was applied per well. Plates were incubated at 21–26 degrees C for 30 minutes, aspirated, washed three additional times, aspirated, and dried.

2.6. Microplate Storage

After drying at 21−26 degrees C for 18−24 hrs in a clean, covered container, test plates were sealed with acetate plate sealers and stored at room temperature until needed. Individual plates were used for both specific IgE and specific (kappa + lambda) assays.

The specific IgE immunoassay entailed use of 100 uL/well of neat subject serum that had been spiked with 1 mg/mL aminated hydrophilic linker solution to neutralize potential, antilinker antibodies (50 μL linker solution per 12 mL serum). Plates were sealed and incubated for 2 hours at 21–26 degrees C and then washed four times with PBST (250 μL/well followed by immediate aspiration). 100 μL of 4 μg/mL biotinylated, goat anti-human IgE was applied per well. (The anti-IgE solution comprised 96 μL of Vector Labs, Burlingame, CA, Product no. BA-3040 added to 11.9 mL of conjugate diluent (10 mg/mL recombinant HSA in PBST +0.25% PEG 4000)). After incubation for 2 hours at 21–26 degrees C, the plates were washed and 100 uL/well of 64 ng/mL streptavidin horseradish peroxidase (Thermo Scientific Product No. 21126 diluted in HSA conjugate diluent) applied. Test plates were incubated for 30 minutes at 21−26 degrees C and then washed. 100 uL/well of Thermo Scientific Chemiluminescence substrate (Product No. 37074) was applied and the plate(s) read 1−3 minutes after application using a Luminoskan Ascent Microplate Luminometer (Thermo Scientific, Waltham, MA, USA).

2.7. Specific (Kappa + Lambda) Test Portion

The linker-spiked test serum sample used in the specific IgE assay was diluted 1/25,000 by (a) making a 1/100 dilution mixing together 100 μL linker-spiked serum and 9.9 mL PBST and (b) spiking 11.950 HSA conjugate diluent with 48 μL of the 1/100 diluted serum. Plates were filled with 100 μL/well of 1/25 k diluted serum, sealed, and incubated for 2 hours at 21–26 degrees C. Equal volumes of Vector biotinylated, goat anti-human kappa antibody (BA-3060) plus biotinylated, goat anti-human lambda antibody (BA-3070) were mixed together to form a 50 : 50 biotinylated anti-(kappa + lambda) concentrate (500 μg/mL). 96 μL of the anti-(kappa + lambda) concentrate was mixed with 11.9 mL of HSA conjugate diluent and 100 μL of the resulting solution applied per well. After 2-hour incubation at 21–26 degrees C, plates were washed and 100 uL per well of 16 ng/mL streptavidin horseradish peroxidase solution applied. Test plates were incubated at 21–26 degrees C for 30 minutes, aspirated, and washed. 100 uL/well of Thermo Scientific chemiluminescence substrate was applied and the plates read at 1–3 minutes after application.

2.8. Individual IgE/(Kappa + Lambda) Determinations

Specific IgE and matching specific (kappa + lambda) signals were obtained by reading corresponding, matched test plates on the microplate luminometer. Average test values corresponding to individual mimotopic peptides were determined by discarding the highest and lowest of four values and averaging the remaining two. The same procedure was followed for the four background well values, together with calculation of twice the standard deviation of the two-point average. The blank well background was deemed to be its average value plus twice the standard deviation. The plate blank well value was subtracted from each peptide-coated well average to yield a net signal. Kappa + lambda values were multiplied by 25,000 in order to delineate the corresponding neat serum (undiluted) epitope-specific kappa + lambda antibody levels. IgE/(K+L) values were multiplied by 1,000,000 in order to bring each quotient to a positive number if attainable. Test results with negative values or values of less than 0.5 were assumed to be test negative.

2.9. Serum Sample Selection

Disease-positive and disease-negative (control) sera were purchased from BioServe (Beltsville, MD, USA). Multiple sclerosis-positive samples were from patients who had not yet received MS-specific therapy, patients who were taking interferon and/or Copaxone (glatiramer acetate) with or without medication shown to be immunosuppressive (Tables 3(a)–3(e)), and patients who were only being treated with immunosuppressive substances.

Anti-inflammatory Agent (ID no. marked yellow on individual plots)Immunosuppressive effectReferences

 (1) MesalazinePotent and specific inhibitor of nuclear factor kappa B.[24]
 (2) Dilantin (phenytoin sodium)Humoral immune suppressant.[25]
 (3) ZonisamideSuppression of IFN-gamma Production by Lymphocytes.[26]
Atypical Antipsychotics
 (4) Olanzapine (Zyprexa, etc.)Suppress tumor necrosis factor, (TNF)-alpha, interleukin (IL)-6, and upregulates IL-10.[27]
 (5) Alprazolam ( Xanax)Inhibits proliferative responses of both B- and T-cells.[28]
 (6) ClonazepamDepression of cellular and humoral immune response.[29]
 (7) DiltiazemInduces direct immunosuppression.[30].
 (8) Diazepam (Valium)Markedly suppresses Antigen-specific antibody production and T-cell reactivity.[31]
Colesterol Lowering Drugs
 (9) Atorvastatin (Lipitor)Increases in IL-10 production.
IL-10 mediates immune suppression.
 (10) Fenofibrate (reduces
A Peroxisome proliferator-activated receptor alpha agonist.[33]
 (11) PravastatinB, lymphocyte and T lymphocyte suppression.[34]
 (12) Rosuvastatin (Crestor)Posttranscriptional level of genetic expression of inflammatory process.[35]
 (13) Simvastatin (Zocor)Mediates induction of Foxp3(+)
T Cells Which Mediate Immuno-Suppression.
Dopamine Reuptake Inhibitors (Antidepressants)
 (14) Bupropion (Wellbutrin, etc.)Involved in inhibiting neuroimmunomodulation.[37]
SerotoninNorepinephrine Reuptake Inhibitors (SNRIs, Antidepressants):
 (15) VenlafaxineSuppresses proinflammatory cytokines.[38]
Selective Serotonin Reuptake Inhibitors (SSRIs, antidepressants):
 (16) Paroxetine (trade names:
    Seroxat, Paxil)
Inhibits splenocyte viability.[39]
Decreases CD4 T-helper cells.[40]
 (17) Fluoxetine (Prozac)Decreases T Lymphocyte Activity.[41]
 (18) Sertraline hydrochloride (Zoloft)Suppression of antigen-specific T(H)1 responses. Inhibition of interferon gamma and stimulation of interleukin-10.[42]
 (19) ClomipramineAs per sertraline.[43]
 (20) Trazodone (Desryl, Oleptro,
   Beneficat, Deprax, Desirel,
    Molipaxin, Thombran, Trittico,
As per sertaline.[43]
Other Immunnosuppressants (1):
 (21) AmantadineInhibits antigen-specific T- and NK-Cell Responses.[44]
 (22) Amitriptyline (Elavil, Tryptizol,
   Laroxyl, Sarotex)
Decrease in the Proliferation of Slenocytes and in NK Activity.[45]
 (23) Clonidine (a direct-acting α2
   adrenergic agonist).
Stimulates production of IL-10 (an anti-Inflammatory cytokine that reduces serum antibody production.)[46]
 (24) Depakote (Valproate semisodium
   used to treat major depressive
Suppresses IL-6- and/or IL-6R-related mechanisms.[42]
 (25) Donepezil (Aricept)Reversible Acetylcholinesterase Inhibitor. Suppresses Neuroinflammation of the Brain.[47]
 (26) Mitoxantrone (Novantrone)Chemotherapeutic agent, depletes B cells.[48]
 (27) Levoxyl (Levothyroxine,
Inhibits cytokine production in T cells.[49]
 (28) Warfarin (Coumadin)Suppresses IL-6 secretion.
Serves as immunosuppressant.
Other Immunnosuppressants (2):
 (29) Heroin and Methadone.Suppression of Cellular and Humoral Immunity.[51]
 (30) Morphine.Suppression of Cellular and Humoral Immunity.[51]
 (31) Oxycodone & PropoxypheneSuppression of Cellular and Humoral Immunity.[51]
 (32) PrednisoneCatabolic Steroid.
Suppression of Cellular and Humoral Immunity.

3. Results

3.1. Control Subjects

As depicted in Figures 17 and 18, neither female ( 𝑛 = 1 0 ) nor male ( 𝑛 = 1 0 ) age-varied, control serum samples were MS test positive by exhibiting IgE/(kappa + lambda) dimer-positive results. Being positive, the control sera would have been IgE/(kappa + lambda) positive when tested against the PLP ADARM peptide antigen (Figures 13) and/or the non-PLP peptides listed on the left-most column of Table 4 that were properly dimer paired. The proper pairings are depicted on Figures 5-6 and Figures 815.

MS-specific peptides sequences for diagnosis and therapy
Myelin proteinFull-length mimotopic peptidesHIConstituent, single-epitope, pentameric equivalentsHI

VTLRI −2.5 VTLRI −2.5
MOGi.c.IENLH −0.9 IENLH −0.9
LHRTF −2.2
MBPi.c.Isoforms 1,2DNEVFGEA4.7DNEVF2.2
"VFGEA −1.5
Isoforms 1,2QDTAVT0.4QDTAV0.8
Isoforms 1,2PKNAW −1 PKNAW −1
MBPi.c.Isoforms 1,2DNTFKD6.3DNTFK3.3
Isoforms 1,2LQTIQE −1 LQTIQ-3.6
MBPi.c.Isoform 1KDSHHPA3KDSHH5.3
"SHHPA −1.2
Isoforms 1,3HGRTQ2.3HGRTQ2.3
MBPi.c.Isoforms 3YKDSHHPA2.5YKDSH2.5
SHHPA −1.2

Bold: cornerstone epitopes.
3.2. Untreated MS Patients

Five MS patients who had not taken Copaxone, beta interferons, or immunosuppressive agents were MS test positive (Figure 19). All were IgE dimer positive against PLP. Three of five patients were also MOG dimer-positive. Of the latter group, all three were myelin surface positive and two patients were also positive against subsurface MOG epitopes (positives are highlighted in yellow). None were MBP dimer positive.

3.3. Patients Taking Copaxone or Interferon Only (Figure 20)

All three patients were dimer positive against the sole PLP epitope, ADARM, irrespective of whether each had relapsing remitting (RR), secondary progressive (SP), or primary progressive (PP) MS. Individual test scores were lower than scores for the untreated MS group. None was IgE dimer positive against MOG or MBP.

3.4. Patients Taking Interferon + Immunosuppressive Agents (Figure 21)

One of twelve patients was PLP dimer test positive. None were positive against MOG or MBP. (Potentially immunosuppressive, ancillary agents are numerically identified in yellow at the bottom of the figure and referenced in Table 3.)

3.5. Patients Only Taking Immunosuppressive Agents (Figure 22)

Four of fourteen test subjects were PLP IgE dimer test positive, irrespective of disease classification. None was IgE dimer positive against MOG or MBP. (Immunosuppressive agents are identified in yellow at the bottom of the figure and referenced in Table 3.)

3.6. Patients Taking Copaxone plus Immunosuppressive Agents (Figure 23)

Only one of six patients was PLP and MOG dimer test positive. None was MBP dimer positive. (Immunosuppressive agents are identified in yellow at the bottom of the figure and referenced in Table 3.)

4. Discussion

The test data is both an affirmation and a significant challenge to the theories and work of other investigators. It affirms the premise that MS is a humoral autoimmune disease as validated by clinicians who have worked with Natalizumab (Tysabri), a humanized monoclonal antibody whose therapeutic use results in a systemic increase in B lymphocytes and, ultimately, plasma cells and specific serum autoantibodies [5254]. Where it differs is in affording a precise explanation of the multilayered humoral MS process and how it might be remedied.

We have concluded that multiple sclerosis is a complex, humoral autoimmune disease caused by IgE dimer formation on the surface or immediate subsurface of CNS myelin that results in focal mast cell degranulation. The degranulating mast cells likely release proteolytic enzymes and possibly other factors that damage or destroy proximal neurons.

Test results of MS patients taking medication shown to have an immunosuppressive effect suggest either interference with the IgE/competing antibody pathological process or with the MS test itself. This was inferred by the quantitative difference in MS test scores between the patients who were taking no medication and exhibited relatively high test scores, patients who were being treated with a single MS-specific pharmaceutical (beta interferon or Copaxone), but had relatively low positive test scores, and patients who were taking the described immunosuppressive agents, with or without interferon or Copaxone, and were only sporadically MS test positive.

This suggests that the conventional, multiple therapy approach may potentially hinder therapeutic efficacy by altering normal immune function.

As interferon and Copaxone are prescribed because of their MS-specific, immunosuppressive, effect and MS is likely an autoimmune disease, it is reasonable to expect some decrease in humoral immune function among specifically treated patients, as reflected by the low anti-PLP test scores exhibited in Figure 20. However, the test scores of MS patients who were also receiving ancillary substances that have been shown to be immunosuppressive (Figures 2123), infer that augmentation of immune suppression may not always be therapeutically beneficial. Another possibility is that the MS-specific and ancillary pharmaceuticals may also hinder serum immunoassay function making some or all specific immunoassays diagnostically unreliable.

Also suggested is the possibility that (1) the ancillary medications, having only been in use since the early twentieth century, may have historically played an instigating or promoting role in MS causation and/or progression through disruption of homeostatic, immune system controls.

The absence of MS test-positive results against MBP dimers may have been due to their deep, intracellular location and relative freedom from immune surveillance and pathological action. It may also indicate that (a) successful MBP humoral targeting first calls for myelin surface disruption via action against PLP and/or outer MOG in order to provide penetrating access for anti-MBP antibodies and/or lymphocytes; (b) MBP is an autoimmune target, but of lesser frequency or importance than the epitopes on the outer surface or immediate sub-surface of myelin.

If MS proves to be an IgE dimer-driven, humoral autoimmune disease, as is suggested by the test data, treatment with mimotopic peptides homologous to those used in the diagnostic immunoassay might prove to be therapeutically beneficial by neutralizing anti-myelin IgE antibodies. The therapeutic peptides would need to be administered in such a way as to insure intravascular delivery of quantities sufficient to neutralize all epitope-specific dimeric IgE autoantibodies through antibody-to-peptide complexing or by neutralizing key epitope-specific IgE antibodies whose target epitopes are cornerstones of a number of pathological dimers. The elimination of one or two dimer-point-specific autoantibodies could prevent multi-site-initiated mast cell degranulation and halt the pathological autoimmune process.

Cornerstone dimer-blocking peptides are highlighted in bold within the full array of potentially therapeutic peptides listed in the sixth column from the left of Table 4 and whose corresponding epitopes and dimers are illustrated in Figures 4 thru 15.

To be effective, therapeutic peptides would need to (a) possess an exact structural match with the specific myelin protein epitope; (b) be of sufficient length (5-6 amino acids) to easily fit and be avidly bound by a single autoantibody; (c) be relatively hydrophilic so as to be functionally soluble when injected or ingested; (d) if ingested, be aided in enteric absorption by pharmaceutical agents such as medium-chain fatty acid constructs [55], superporous hydrogels [56], or N-trimethyl chitosan chloride [57].

5. Summary

Evidence is presented that multiple sclerosis is a humoral autoimmune disease caused by IgE dimer formation on the surface or immediate subsurface of CNS myelin that results in focal mast cell degranulation with release of tissue-damaging enzymes and/or other substances.

Conflict of Interests

The author has no conflict of interests that would prevent acceptance or publication of this paper.


The author wishes to thank Lee Munder, Steve Holland, Larry James, Andrew Milner, Bill Lipton, and Greg Hermanson for their efforts and dedication to the MS diagnostic project and Michael Verlander for his comments and helpful suggestions in composing this article.


  1. W. Göpel, H. Benkenstein, and M. Banzhaf, “Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases,” Deutsche Gesundheitswesen, vol. 27, no. 41, pp. 1955–1961, 1972. View at: Google Scholar
  2. L. Jacobs, J. O'Malley, A. Freeman, and R. Ekes, “Intrathecal interferon reduces exacerbations of multiple sclerosis,” Science, vol. 214, no. 4524, pp. 1026–1028, 1981. View at: Google Scholar
  3. J. R. Berger, “Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies,” American Journal of Managed Care, vol. 17, supplement 5, pp. S146–S153, 2011. View at: Google Scholar
  4. D. D. Mikol, C. Ditlow, D. Usatin et al., “Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients,” Journal of Neuroimmunology, vol. 180, no. 1-2, pp. 40–49, 2006. View at: Publisher Site | Google Scholar
  5. V. H. Secor, W. E. Secor, M. A. Brown, and C. A. Gutekunst, “Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis,” Journal of Experimental Medicine, vol. 191, no. 5, pp. 813–821, 2000. View at: Publisher Site | Google Scholar
  6. M. A. Brown, M. B. Tanzola, and M. Robbie-Ryan, “Mechanisms underlying mast cell influence on EAE disease course,” Molecular Immunology, vol. 38, no. 16–18, pp. 1373–1378, 2002. View at: Publisher Site | Google Scholar
  7. N. Medic, P. Lorenzon, F. Vita et al., “Mast cell adhesion induces cytoskeletal modifications and programmed cell death in oligodendrocytes,” Journal of Neuroimmunology, vol. 218, no. 1-2, pp. 57–66, 2010. View at: Publisher Site | Google Scholar
  8. M. Z. M. Ibrahim, “The mast cells of the mammalian central nervous system: part 2. The effect of proton irradiation in the monkey,” Journal of the Neurological Sciences, vol. 21, no. 4, pp. 479–499, 1974. View at: Publisher Site | Google Scholar
  9. G. N. Dietsch and D. J. Hinrichs, “Mast cell proteases liberate stable encephalitogenic fragments from intact myelin,” Cellular Immunology, vol. 135, no. 2, pp. 541–548, 1991. View at: Publisher Site | Google Scholar
  10. D. Johnson, P. A. Seeldrayers, and H. L. Weiner, “The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation,” Brain Research, vol. 444, no. 1, pp. 195–198, 1988. View at: Google Scholar
  11. M. Z. Ibrahim, A. T. Reder, R. Lawand, W. Takash, and S. Sallouh-Khatib, “The mast cells of the multiple sclerosis brain,” Journal of Neuroimmunology, vol. 70, no. 2, pp. 131–138, 1996. View at: Publisher Site | Google Scholar
  12. J. M. Paar, N. T. Harris, D. Holowka, and B. Baird, “Bivalent ligands with rigid double-stranded DNA spacers reveal structural constraints on signaling by FcεRI,” Journal of Immunology, vol. 169, no. 2, pp. 856–864, 2002. View at: Google Scholar
  13. J. Newcombe, S. Gahan, and M. L. Cuzner, “Serum antibodies against central nervous system proteins in human demyelinating disease,” Clinical and Experimental Immunology, vol. 59, no. 2, pp. 383–390, 1985. View at: Google Scholar
  14. H. Hashizume, B. K. G. Theng, and A. Yamagishi, “Adsorption and discrimination of alanine and alanyl-alanine enantiomers by allophane,” Clay Minerals, vol. 37, no. 3, pp. 551–557, 2002. View at: Publisher Site | Google Scholar
  15. T. P. Hopp and K. R. Woods, “Prediction of protein antigenic determinants from amino acid sequences,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 6 I, pp. 3824–3828, 1981. View at: Google Scholar
  16. K. E. Kronquist, B. F. Crandall, W. B. Macklin, and A. T. Campagnoni, “Expression of myelin proteins in the developing human spinal cord: cloning and sequencing of human proteolipid protein cDNA,” Journal of Neuroscience Research, vol. 18, no. 3, pp. 395–401, 1987. View at: Google Scholar
  17. Sanger 1. Myelin Oligodendrocyte Glycoprotein Isoform CAQ08210 Amino Acid Sequence, Wellcome Trust Sanger Institute, Hinxton, UK, 2009.
  18. MBP Isoform 1, E. H. Eylar, S. Brostoff, G. Hashim, J. Caccam, and P. Burnett, “Basic A1 protein of the myelin membrane. The complete amino acid sequence,” Journal of Biological Chemistry, vol. 246, no. 18, pp. 5770–5784, 1971. View at: Google Scholar
  19. MBP Isoform 2 and E. H. Eylar, a s per MBP Isoform 1 minus amino acids 193–304.
  20. MBP Isoform 3 and E. H. Eylar, as per MBP Isoform 1 minus amino acids 1–133 and amino acid 192 is substituted by KVPWLKPGRSPLPSHARSQPGLCNMYK.
  21. D. D. Mikol, J. R. Gulcher, and K. Stefansson, “The oligodendrocyte-myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate,” Journal of Cell Biology, vol. 110, no. 2, pp. 471–479, 1990. View at: Google Scholar
  22. J. M. Bronstein, S. Tiwari-Woodruff, A. G. Buznikov, and D. B. Stevens, “Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: role in biology and disease,” Journal of Neuroscience Research, vol. 59, no. 6, pp. 706–711, 2000. View at: Publisher Site | Google Scholar
  23. C. Wahl, S. Liptay, G. Adler, and R. M. Schmid, “Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B,” Journal of Clinical Investigation, vol. 101, no. 5, pp. 1163–1174, 1998. View at: Google Scholar
  24. A. H. Badawy, S. A. Shalaby, and S. F. Abdel Aal, “Hydantoin immunosuppression clinical study,” Journal of the Egyptian Society of Parasitology, vol. 21, no. 1, pp. 257–262, 1991. View at: Google Scholar
  25. M. Yamada, M. Ohkawa, K. Tamura et al., “Anticonvulsant-induced suppression of IFN-γ production by lymphocytes obtained from cervical lymph nodes in glioma-bearing mice,” Journal of Neuro-Oncology, vol. 47, no. 2, pp. 125–132, 2000. View at: Publisher Site | Google Scholar
  26. H. Sugino, T. Futamura, Y. Mitsumoto, K. Maeda, and Y. Marunaka, “Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, pp. 303–307, 2009. View at: Publisher Site | Google Scholar
  27. M. P. Chang, S. C. Castle, and D. C. Norman, “Suppressive effects of alprazolam on the immune response of mice,” International Journal of Immunopharmacology, vol. 13, no. 2-3, pp. 259–266, 1991. View at: Google Scholar
  28. T. C. Sorrell and I. J. Forbes, “Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro,” Clinical and Experimental Immunology, vol. 20, no. 2, pp. 273–285, 1975. View at: Google Scholar
  29. A. D'Ambrosio, G. Segoloni, and F. Quintieri, “The modulatory effect of diltiazem on human in vitro alloreactivity when used alone or in combination with cyclosporin A and/or methylprednisolone,” Transplant International, vol. 10, no. 6, pp. 426–431, 1997. View at: Publisher Site | Google Scholar
  30. S. P. Wey, H. Y. Wu, F. C. Chang, and T. R. Jan, “Methamphetamine and diazepam suppress antigen-specific cytokine expression and antibody production in ovalbumin-sensitized BALB/c mice,” Toxicology Letters, vol. 181, no. 3, pp. 157–162, 2008. View at: Publisher Site | Google Scholar
  31. F. Paul, S. Waiczies, J. Wuerfel et al., “Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis,” Plos One, vol. 3, no. 4, Article ID e1928, 2008. View at: Publisher Site | Google Scholar
  32. C. Delayre-Orthez, J. Becker, J. Auwerx, N. Frossard, and F. Pons, “Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate,” European Journal of Pharmacology, vol. 581, no. 1-2, pp. 177–184, 2008. View at: Publisher Site | Google Scholar
  33. J. A. Kobashigawa, H. Laks, D. C. Drinkwater et al., “The University of California at Los Angeles experience in heart transplantation,” Clinical Transplants, pp. 129–135, 1995. View at: Google Scholar
  34. W. M. Schmidt, A. O. Spiel, B. Jilma, M. Wolzt, and M. Müller, “In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model,” Pharmacogenetics and Genomics, vol. 18, no. 2, pp. 109–120, 2008. View at: Publisher Site | Google Scholar
  35. Y. C. Kim, K. K. Kim, and E. M. Shevach, “Simvastatin induces Fox p3+ T-regulatory cells by modulation of transforming growth factor-β signal transduction,” Immunology, vol. 130, no. 4, pp. 484–493, 2010. View at: Publisher Site | Google Scholar
  36. L. Devoino, G. Idova, E. Alperina, and M. Cheido, “Brain neuromediator systems in the immune response control: pharmacological analysis of pre- and postsynaptic mechanisms,” Brain Research, vol. 633, no. 1-2, pp. 267–274, 1994. View at: Publisher Site | Google Scholar
  37. P. Vollmar, S. Nessler, S. R. Kalluri, H. P. Hartung, and B. Hemmer, “The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines,” International Journal of Neuropsychopharmacology, vol. 12, no. 4, pp. 525–536, 2009. View at: Publisher Site | Google Scholar
  38. M. Taler, M. Bar, I. Korob et al., “Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders,” International Immunopharmacology, vol. 8, no. 4, pp. 526–533, 2008. View at: Publisher Site | Google Scholar
  39. R. Pacifici, S. Pichini et al., “Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders,” Journal of Pharmacology and Experimental Therapeutics, vol. 309, pp. 285–292, 2004. View at: Google Scholar
  40. T. C. Pellegrino and B. M. Bayer, “Role of central 5 -HT (2) receptors in fluoxetine-Induced decreases in T lymphocyte activity,” Brain, Behavior, and Immunity, vol. 16, pp. 87–103, 2002. View at: Google Scholar
  41. M. Maes, E. Bosnians, J. Calabrese, R. Smith, and H. Y. Meltzer, “Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers,” Journal of Psychiatric Research, vol. 29, no. 2, pp. 141–152, 1995. View at: Publisher Site | Google Scholar
  42. M. Maes, A. Lin et al., “Negative immunoregulatory effects of noradrenalin through alpha2 -adrenoceptor activation,” Neuroendocrinology Letters, vol. 21, pp. 375–382, 2000. View at: Google Scholar
  43. M. R. Mardiney Jr. and A. B. Bredt, “The immunosuppressive effect of amantadine upon the response of lymphocytes to specific antigens in vitro,” Transplantation, vol. 12, no. 3, pp. 183–188, 1971. View at: Google Scholar
  44. M. Kubera, A. Basta-Kaim, A. Skowron-Cendrzak, B. Mazur-Kolecka, A. Roman, and J. Borycz, “Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity,” Polish Journal of Pharmacology, vol. 47, no. 4, pp. 321–326, 1995. View at: Google Scholar
  45. Y. Yoshiyama, “Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse,” Clinical Neurology, vol. 48, no. 11, pp. 910–912, 2008. View at: Google Scholar
  46. J. Ashton-Chess, G. Meurette, G. Karam et al., “The study of mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons: comparison with cyclophosphamide,” Xenotransplantation, vol. 11, no. 2, pp. 112–122, 2004. View at: Publisher Site | Google Scholar
  47. C. Yao, J. Zhang, L. Wang, Y. Guo, and Z. Tian, “Inhibitory effects of thyroxine on cytokine production by T cells in mice,” International Immunopharmacology, vol. 7, no. 13, pp. 1747–1754, 2007. View at: Publisher Site | Google Scholar
  48. M. Kurohara, H. Yasuda, H. Moriyama et al., “Low-dose warfarin functions as an immunomodulator to prevent cyclophosphamide-induced NOD diabetes,” Kobe Journal of Medical Sciences, vol. 54, no. 1, pp. E1–E13, 2008. View at: Google Scholar
  49. P. T. Thomas, R. V. House, and H. N. Bhargava, “Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone,” General Pharmacology, vol. 26, no. 1, pp. 123–130, 1995. View at: Publisher Site | Google Scholar
  50. R. Vallejo, O. de Leon-Casasola, and R. Benyamin, “Opioid therapy and immunosuppression: a review,” American Journal of Therapeutics, vol. 11, no. 5, pp. 354–365, 2004. View at: Google Scholar
  51. L. Manchikanti, K. N. Manchikanti, V. Pampati, and K. A. Cash, “Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain,” Pain Physician, vol. 12, no. 1, pp. 259–267, 2009. View at: Google Scholar
  52. A. H. Cross and E. Waubant, “MS and the B cell controversy,” Biochimica et Biophysica Acta, vol. 1812, no. 2, pp. 231–238, 2011. View at: Publisher Site | Google Scholar
  53. L. Kappos, D. Li, P. A. Calabresi et al., “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial,” The Lancet, vol. 378, no. 9805, pp. 1779–1787, 2011. View at: Publisher Site | Google Scholar
  54. C. Holmén, F. Piehl, J. Hillert et al., “A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis,” Multiple Sclerosis, vol. 17, no. 6, pp. 708–719, 2011. View at: Publisher Site | Google Scholar
  55. T. W. Leonard, J. Lynch, M. J. McKenna, and D. J. Brayden, “Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET,” Expert Opinion on Drug Delivery, vol. 3, no. 5, pp. 685–692, 2006. View at: Publisher Site | Google Scholar
  56. A. Polnok, J. C. Verhoef, G. Borchard, N. Sarisuta, and H. E. Junginger, “In vitro evaluation of intestinal absorption of desmopressin using drug-delivery systems based on superporous hydrogels,” International Journal of Pharmaceutics, vol. 269, no. 2, pp. 303–310, 2004. View at: Publisher Site | Google Scholar
  57. S. M. van der Merwe, J. C. Verhoef, J. H. M. Verheijden, A. F. Kotzé, and H. E. Junginger, “Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 58, no. 2, pp. 225–235, 2004. View at: Publisher Site | Google Scholar

Copyright © 2012 Emanuel Calenoff. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.